montelukast dicyclohexylamine

Montelukast dicyclohexylamine (MK0476), a potent, selective, and orally active antagonist of the cysteinyl leukotriene receptor 1 (CysLT1), is utilized in the research of asthma, liver injury, and COVID-19. It exhibits antioxidant properties in the context of intestinal ischemia-reperfusion injury and can mitigate cardiac damage. Additionally, it reduces eosinophil infiltration in the airways of asthmatic patients.

Montelukast alcohol is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies.

Montelukast sodium (MK0476) is an orally available leukotriene receptor antagonist which is widely used for the prophylaxis and chronic treatment of asthma and has been linked to rare cases of clinically apparent liver injury.

Montelukast (Singular) is an orally available leukotriene receptor antagonist which is widely used for the prophylaxis and chronic treatment of asthma and has been linked to rare cases of clinically apparent liver injury.

Montelukast-d6 is a deuterated compound of Montelukast. Montelukast has a CAS number of 158966-92-8. Montelukast is an orally available leukotriene receptor antagonist which is widely used for the prophylaxis and chronic treatment of asthma and has been linked to rare cases of clinically apparent liver injury.